Offering UTI diagnosis in 15 minutes and tailored antibiotic selection in 30, Sysmex’s PA-100 AST System enables swift, effective treatment. A financial model in Spain predicts vast cost savings, and the £8 million Longitude Prize cements the system’s role in combating antimicrobial resistance.
With the PA-100 AST System, Sysmex introduces a rapid, high-precision diagnostic tool that eliminates the long wait for lab results. By combining nanotechnology with rapid AST, the system provides results fast enough to support same-day treatment.
Millions are suffering UTIs globally
UTIs are among the most common bacterial infections, affecting over 400 million people worldwide annually. Delays in diagnosis and reliance on empirical antibiotic treatments often lead to suboptimal outcomes, secondary infections and increased antimicrobial resistance (AMR). Sysmex’s PA-100 AST System bridges this gap with reported sensitivity (84%) and specificity (99%), ensuring timely and precise care while reducing reliance on broad-spectrum antibiotics — a critical step in slowing the rise of AMR.
Alain Baverel, President & CEO Sysmex Europe SE, remarked, “The PA-100 AST System represents a pivotal innovation in the fight against antimicrobial resistance. By providing clinicians with rapid and precise diagnostic insights, we can transform how urinary tract infections are treated globally. This tool not only benefits patients but also strengthens the financial sustainability of healthcare systems.”
Recent budget impact modelling suggests that implementing the PA-100 AST System in Spanish public healthcare settings could contribute to cost efficiencies in UTI management. The analysis projects potential savings of approximately €323 million in the first year assuming 100% adoption, with projections indicating cumulative cost reductions over three years. These stem from anticipated reductions in secondary complications, hospital admissions and indirect costs such as productivity losses.
Takashi Ono, Member of the Managing Board and Senior Executive Officer & Managing Director of Sysmex Corporation, commented, “By addressing one of the leading causes of antibiotic misuse, Sysmex’s PA-100 AST System aligns perfectly with global efforts to combat antimicrobial resistance. The system empowers healthcare providers with the data needed to make the right decision at the right time, benefiting patients and public health alike.”
PA-100 AST System was awarded the Longitude Prize
Beyond its economic and clinical utility, the system’s achievements have been widely recognised. Last year, the PA-100 AST System was awarded the Longitude Prize, an £8 million award dedicated to innovations addressing AMR. This accolade underscores the system’s capacity to enhance patient outcomes and mitigate the global AMR crisis.
Identifies bacteriuria within 15 minutes
The PA-100 AST System’s innovative approach utilises a compact, smartphone-sized cartridge to identify bacteriuria in 15 minutes & determine effective antibiotics in the subsequent 30 minutes. This reduces treatment delays and complications.
